Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis

Author： Nuijten Mark J.C.   Wittenberg Wolfgang   Lebmeier Maximilian  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.25, Iss.1, 2007-01, pp. : 55-71

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis: A Critical and Systematic Review

By PrescottJr William A.   Doloresco Fred   Brown Jack   Paladino Joseph A.  

PharmacoEconomics, Vol. 28, Iss. 4, 2010-04 ,pp. : 279-293

Adis International

Access to resources Recommend Favorite

Palivizumab: A Review of its Use as Prophylaxis for Serious Respiratory Syncytial Virus Infection

By Fenton Caroline   Scott Lesley J.   Plosker Greg L.  

Pediatric Drugs, Vol. 6, Iss. 3, 2004-01 ,pp. : 177-197

Adis International

Access to resources Recommend Favorite

Evaluation of the Safety of Palivizumab in the Second Season of Exposure in Young Children at Risk for Severe Respiratory Syncytial Virus Infection

By Lacaze-Masmonteil T.  

Drug Safety, Vol. 26, Iss. 4, 2003-01 ,pp. : 283-291

Adis International

Access to resources Recommend Favorite

Palivizumab for RSV prevention in high-risk children

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 520, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Palivizumab for RSV prevention in high-risk children

By  

Inpharma, Vol. 1, Iss. 1573, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite